Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16186920 | 1.00 | LMNA (0.45) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL8594108 | 0.95 | — | — | |
| SCHEMBL8616181 | 0.95 | — | — | |
| SCHEMBL16186919 | 0.87 | — | — | |
| SCHEMBL9609827 | 0.87 | — | — | |
| SCHEMBL9609820 | 0.83 | — | — | |
| SCHEMBL9609862 | 0.83 | — | — | |
| SCHEMBL16186939 | 0.83 | — | — | |
| SCHEMBL9609823 | 0.82 | — | — | |
| SCHEMBL16186940 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20140315927-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | LMNA 3814/4885HTT 2545/4885SMN1; SMN2 4296/4885 |
| US-20120136023-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | LMNA 3814/4885HTT 2545/4885SMN1; SMN2 4296/4885 |
| US-20140315927-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | LMNA 3814/4885HTT 2545/4885SMN1; SMN2 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.